Josep Comín-Colet1, Darío Rubio-Rodríguez2, Carlos Rubio-Terrés2, Cristina Enjuanes-Grau3, Florian S Gutzwiller4, Stefan D Anker5, Piotr Ponikowski6. 1. Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, Instituto de Investigaciones Médicas (IMIM), Hospital del Mar, Barcelona, Spain; Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain. Electronic address: jcomin@hospitaldelmar.cat. 2. Health Value, Madrid, Spain. 3. Programa de Insuficiencia Cardiaca, Servicio de Cardiología, Hospital del Mar, Barcelona, Spain; Grupo de Investigación Biomédica en Enfermedades del Corazón, Programa de Investigación en Procesos Inflamatorios y Cardiovasculares, Instituto de Investigaciones Médicas (IMIM), Hospital del Mar, Barcelona, Spain; Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain. 4. Institute of Pharmaceutical Medicine/ECPM, University of Basel, Basel, Switzerland. 5. Department of Cardiology, Virchow-Klinikum, Charité Universitätsmedizin, Berlin, Germany. 6. Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
Abstract
INTRODUCTION AND OBJECTIVES: Treatment with ferric carboxymaltose improves symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency. The aim of this study was to assess the cost-effectiveness of ferric carboxymaltose treatment vs no treatment in these patients. METHODS: We used an economic model based on the Spanish National Health System, with a time horizon of 24 weeks. Patient characteristics and ferric carboxymaltose effectiveness (quality-adjusted life years) were taken from the Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure trial. Health care resource use and unit costs were taken either from Spanish sources, or from the above mentioned trial. RESULTS: In the base case analysis, patients treated with and without ferric carboxymaltose treatment acquired 0.335 and 0.298 quality-adjusted life years, respectively, representing a gain of 0.037 quality-adjusted life years for each treated patient. The cost per patient was €824.17 and €597.59, respectively, resulting in an additional cost of €226.58 for each treated patient. The cost of gaining 1 quality adjusted life year with ferric carboxymaltose was €6123.78. Sensitivity analyses confirmed the robustness of the model. The probability of ferric carboxymaltose being cost-effective (< €30 000 per quality-adjusted life year) and dominant (more effective and lower cost than no treatment) was 93.0% and 6.6%, respectively. CONCLUSIONS: Treatment with ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, is cost-effective in Spain.
INTRODUCTION AND OBJECTIVES: Treatment with ferric carboxymaltose improves symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency. The aim of this study was to assess the cost-effectiveness of ferric carboxymaltose treatment vs no treatment in these patients. METHODS: We used an economic model based on the Spanish National Health System, with a time horizon of 24 weeks. Patient characteristics and ferric carboxymaltose effectiveness (quality-adjusted life years) were taken from the Ferinject® Assessment in patients with IRondeficiency and chronic Heart Failure trial. Health care resource use and unit costs were taken either from Spanish sources, or from the above mentioned trial. RESULTS: In the base case analysis, patients treated with and without ferric carboxymaltose treatment acquired 0.335 and 0.298 quality-adjusted life years, respectively, representing a gain of 0.037 quality-adjusted life years for each treated patient. The cost per patient was €824.17 and €597.59, respectively, resulting in an additional cost of €226.58 for each treated patient. The cost of gaining 1 quality adjusted life year with ferric carboxymaltose was €6123.78. Sensitivity analyses confirmed the robustness of the model. The probability of ferric carboxymaltose being cost-effective (< €30 000 per quality-adjusted life year) and dominant (more effective and lower cost than no treatment) was 93.0% and 6.6%, respectively. CONCLUSIONS: Treatment with ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, is cost-effective in Spain.
Authors: Tee Joo Yeo; Poh Shuan Daniel Yeo; Farid Abdul Hadi; Timothy Cushway; Kim Yee Lee; Fang Fang Yin; Anne Ching; Ruili Li; Seet Yoong Loh; Shir Lynn Lim; Raymond Ching-Chiew Wong; Bee Choo Tai; Arthur Mark Richards; Carolyn S P Lam Journal: ESC Heart Fail Date: 2018-01-18
Authors: Phil McEwan; Piotr Ponikowski; Jason A Davis; Giuseppe Rosano; Andrew J S Coats; Fabio Dorigotti; Donal O'Sullivan; Antonio Ramirez de Arellano; Ewa A Jankowska Journal: Eur J Heart Fail Date: 2021-06-30 Impact factor: 15.534